Haloperidol and apomorphine differentially affect neuropeptidase activity

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 1, 1996, Pages 113-120

  Waters, Stephen M ^a   Konkoy, Christopher S ^a   Davis, Thomas P ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; BRAIN ENZYME; DIPEPTIDYL CARBOXYPEPTIDASE; DOPAMINE RECEPTOR STIMULATING AGENT; ENKEPHALIN; HALOPERIDOL; METALLOPROTEINASE; MICROSOMAL AMINOPEPTIDASE; NEUROPEPTIDASE; NEUROTENSIN; SUBSTANCE P; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG MECHANISM; ENZYME ACTIVITY; FRONTAL CORTEX; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT; RECEPTOR BINDING;

ANIMALS; ANTIGENS, CD13; ANTIPSYCHOTIC AGENTS; APOMORPHINE; CAUDATE NUCLEUS; DOPAMINE AGONISTS; FRONTAL LOBE; HALOPERIDOL; MALE; METALLOENDOPEPTIDASES; NEPRILYSIN; NEUROPEPTIDES; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030439667     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. 8. J. Neurochem. 48: 284-292, 1987.
2. BANNON, M. J., LEE, J.-M., GIRAUD, P., YOUNG, A., AFFOLTER, H.-U. AND BONNER, T. I.: Dopamine antagonist haloperidol decreases substance P, and preprotachykinin mRNAs in rat striatonigral neurons. J. Biol. Chem. 261: 6640-6642, 1986.
3. BARNES, K., TURNER, A. J. AND KENNY, A. J.: Electromicroscopic immunocytochemistry of pig brain shows that endopeptidase-24.11 is localized in neuronal membranes. Neurosci. Lett. 94: 64-69, 1988.
4. BATEMAN, R, C. AND HERSH, L. B.: Evidence for an essential histidine in neutral-endopeptidase 24.11. Biochemistry 26: 4237-4455, 1987.
5. BENFIELD, M. C., MEYER, D. K., ESKAY, R. L., JENSEN, J. T. AND BROWNSTEIN, M. J.: The distribution of cholecystokinin-immunoreactivity in the central nervous system of the rat, as determined by radioimmunoassay. Brain Res. 212: 51-57, 1981.
6. BLAHA, C. D. AND PHILLIPS, A. G.: Pharmacological evidence for common mechanisms underlying the effects of neurotensin and neuroleptics on in vivo dopamine efflux in rat nucleus accumbens. Neuroscience 49: 867-877, 1992.
7. BOURAS, C., SCHULTZ, P., CONSTANTINIDIS, J. AND TISSOT, R.: Differential effects of acute and chronic administration of haloperidol on substance P and enkephalins in diverse rat brain areas. Neuropsychobiology 16: 169-174, 1986.
8. BRADFORD, M. M.: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254, 1976.
9. CADOR, M., RIVET, J.-M., KELLEY, A. E., LE MOAL, M. AND STINUS, L.: Substance P, neurotensin and enkephalin injections into the ventral tegmental area: Comparative study on dopamine turnover in several forebrain structures. Brain Res. 486: 357-363, 1989.
10. CHECLER, F.: Neuropeptide-degrading peptidases. In Methods in Neurotransmitter and Neuropeptide Research, ed. by S. H. Parvez, M. Naoi, T. Nagatsu and S. Parvez, pp. 475-418, Elsevier Science Publishers, New York, 1993.
11. CHRISTIAN, H., ANDREA, K. G., BERNHARD, A., HANS-GUNTHER, K., CHRISTIAN, H., ELVAR, T. AND ALOIS, S : Effects of haloperidol and clozapine on preprotachykinin-A messenger RNA, tachykinin tissue levels, release and neurokinin-1 receptors in the striato-nigral system. Synapse 6: 1-9, 1990.
12. CHU, T. G. AND ORLOWSKI, M.: Soluble metalloendopeptidase from rat brain: Action on enkephalin-containing peptides and other bioactive peptides. Endocrinology 116: 1418-1425, 1985.
13. COOPER, P. E., FERNSTROM, M. H., RORSTAD, O. P., LEEMAN, S. E. AND MARTIN, J. B.: The regional distribution of somatostatin, substance P and neurotensin in human brain. Brain Res 218: 219-232, 1981.
14. CRAWLEY, J. N.: Cholecystokinin-dopamine interactions. Trends Pharmacol. Sci 12: 232-236, 1991.
15. DAHMS, P. AND MENTLEIN, R.: Purification of the main somatostatin-degrading proteases from rat and pig brains, their action on neuropeptides, and their identification as endopeptidases 24.15 and 24.16. Eur. J. Biochem. 208: 145-154, 1992.
16. DAUCH, P., MASUO, Y., VINCENT, J.-P. AND CHECLER, F.: A survey of the cerebral regionalization and ontogeny of eight exo- and endopeptidases in murines. Peptides 14: 593-599, 1993.
17. DAVIS, T. P., GILLESPIE, T. J. AND KONINGS, P. N. M.: Specificity of neurotensin metabolism by regional rat brain slices. J. Neurochem. 58: 608-617, 1992.
18. DE LA BAUME, S., YI, C. C., SCHWARTZ, J. C., CHAILLET, P., MARCAIS-COLLADO, H. M. AND COSTENTIN, J : Participation of both 'enkephalinase' and aminopeptidase activities in the metabolism on endogenous enkephalins. Neuroscienee 8: 143-151, 1983.
19. DELAY-GOYET, P., ZAJAC, J.-M. AND ROQUES, B. P.: Effects of repeated treatment with haloperidol on rat striatal neutral endopeptidase, and on μ- and δ-opioid binding sites: Comparison with chronic morphine and chronic kelatorphan. Neurosci. Lett. 103: 197-202, 1989.
20. ELLIOTT, P. J., NEMEROFF, C. B. AND KILTS, C. D.: Evidence for atonic facilitatory influence of substance P on dopamine release in the nucleus accumbens. Brain Res. 385: 379-382, 1986.
21. EMSON, P. C., ARREGUI, A., CLEMENT-JONES, V., SANDBERG, B. E. B. AND ROSSOR, M.: Regional distribution of methionine-enkephalin and substance P-like immunoreactivity in normal human brain and in Huntington's disease. Brain Res 199: 147-160, 1980.
22. ERDOS, E. G.: The angiotensin I converting enzyme. Fed. Proc. 36: 1760-1765, 1977.
23. ERDÖS, E. G., JOHNSON, A. R. AND BOYDEN, N. T.: Hydrolysis of enkephalin by cultured human endothelial cells and by purified peptidyl dipeptidase. Biochem. Pharmacol. 27: 843-845, 1978.
24. FREY, P.: Cholecystokinin octapeptide levels in rat brain are changed after subchronic neuroleptic treatment. Eur. J. Pharmacol. 95: 87-92, 1983.
25. GEORGE, S. R. AND KERTESZ, M.: Met-enkephalin concentrations in striatum respond reciprocally to alterations in dopamine neurotransmission. Peptides 8: 487-192, 1987.
26. GILLESPIE, T. J., KONINGS, P. N. M., MERRILL, B. J. AND DAVIS, T. P.: A specific enzyme assay for aminopeptidase M in rat brain. Life Sci 51: 2097-2106, 1992.
27. GRAY, E. G. AND WHITTAKER, V. P.: Isolation of nerve endings from brain: An electron microscopic study of cell fragments derived by homogenization and centrifugation. J. Anat. 96: 79-87, 1962.
28. GROS, C., GIROS, B. AND SCHWARTZ, J.-C.: Identification of aminopeptidase M as an enkephalin-degrading enzyme in rat cerebral membranes. Biochemistry 24: 2179-2185, 1985.
29. GYGI, S. P., GIBB, J. W. AND HANSON, G. R.: Differential effects of antipsychotic and psychomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions. J. Pharmacol. Exp. Ther. 270: 192-197, 1994.
30. HERMAN, Z. S., HUZARSKA, M., KMIECIAK-KOLADA, K. AND KOWALSKI, J.: Chronic treatment with chlorpromazine, thioridazine or haloperidol increases striatal enkephalins and their release from rat brain. Psychopharmacology 104: 106-112, 1991.
31. HÖKFELT, T , EVERITT, B. J., THEODORSSON-NORHEIM, E. AND GOLDSTEIN, M.: Occurrence of neurotensin like immunoreactivity in subpopulations of hypothalamic, mesencephalic and medullary catecholamine neurons. J. Comp. Neurol. 222: 543-559, 1984.
32. JOLICOEUR, F. B., GAGNÉ, M. A., RIVEST, R., DRUMHELLER, A. AND ST-PIERRE, S.: Atypical neuroleptic-like behavioral effects of neurotensin. Brain Res. Bull. 32: 487-491, 1993.
33. KENNY, J.: Neuropeptide processing and metabolism. Molecular and clinical aspects. Biochem Soc. Trans 21: 663-668, 1993.
34. KEST, B., ORLOWSKI, M , MOLINEAUX, C. J. AND BODNAR, R. J.: Antinociceptive properties of inhibitors of endopeptidase 24.15. Int. J. Neurosci. 56: 141-149, 1991.
35. KONKOY, C. S. AND DAVIS, T. P.: Regional metabolism of met-enkephalin and CCK on intact rat brain slices: Characterization of specific peptidases. J. Neurochem. 65: 2773-2782, 1995,
36. KONKOY, C. S., OAKES, M. G. AND DAVIS, T. P.: Chronic treatment with neuroleptics alters neutral endopeptidase 24.11 activity in rat brain regions. Peptides 14: 1017-1020, 1993.
37. KONKOY, C. S., WATERS, S. M. AND DAVIS, T. P.: Acute administration of neuroleptics decreases neurotensin metabolism on intact, regional rat brain slices. J. Pharmacol. Exp. Ther. 269: 555-563, 1994.
38. 5]enkephalin metabolism in rat striatum and cortex. Eur. J. Pharmacol., in press, 1996.
39. LI, S. J., SIVAM, S. P., MCGINTY, J. F., HUANG, Y. S. AND HONO, J. S.: Dopaminergic regulation of tachykinin metabolism in the striatonigral pathway. J. Pharmacol. Exp. Ther. 243: 792-798, 1987.
40. MALFROY, B., KADO-FONG, H., GROS, C., GIROS, B., SCHWARTZ, J. C. AND HELLMISS, R.: Molecular cloning and amino acid sequence of rat kidney aminopeptidase M: A member of a super family of zinc-metallohydolases. Biochem. Biophys. Res. Commun. 161: 236-241, 1989.
41. MARCEL, D., POLLARD, H., VERROUST, P., SCHWARTZ, J. C. AND BEAUDET, A.: Electron microscopic localization of immunoreactive enkephalinase (EC 3.4.24.11) in the neostriatum of the rat. J. Neurosci. 10: 2804-2817, 1990.
42. MENTLEM, R AND DAHMS, P.: Endopeptidases 24.16 and 24.15 are responsible for the degradation of somatostatin, neurotensin, and other neuropeptides by cultivated rat cortical astrocytes. J. Neurochem. 62: 27-36, 1994.
43. MERCHANT, K. M., DOBNER, P. R. AND DORSA, D. M.: Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. J. Neurosci. 12: 652-663, 1992.
44. MOLINEAUX, C. J. AND AYALA, J. M.: An inhibitor of endopeptidase-24.15 blocks the degradation of intraventricularly administered dynorphins. J. Neurochem. 55: 611-618, 1990.
45. MOLINEAUX, C. J., YU, B. AND AYALA, J. M.: Distribution of endopeptidase-24.15 in rat brain nuclei using a novel fluorogenic substrate: Comparison with endopeptidase-24 11. Neuropeptides 18: 49-54, 1991.
46. NEMEROFF, C. B.: The interaction of neurotensin with dopaminergic pathways in the central nervous system: Basic neurobiology and implications for the pathogenesis and treatment of schizophrenia. Psychoneuroendocrinology 11: 15-37, 1986.
47. OBLIN, A., DANSE, M. J. AND ZIVKOVIC, B.. Degradation of substance P by membrane peptidases in the rat substantia nigra: Effect of selective inhibitors. Neurosci. Lett. 84: 91-96, 1988.
48. OKUMA, Y., FUKUDA, Y. AND OSUMI, Y.: Neurotensin potentiates the potassium-induced release of endogenous dopamine from rat striatal slices. Eur. J. Pharmacol. 93: 27-33, 1983.
49. ORLOWSKI, M., MICHAUD, C. AND CHU, T. G.: A soluble metalloendopeptidase from rat brain. Purification of the enzyme and determination of specificity with synthetic and natural peptides. Eur. J. Biochem. 185: 81-88, 1983.
50. PAXINOS, G. AND WATSON, C.: The Rat Brain in Stereotaxic Coordinates, 2nd ed., Academic Press, New York, 1986.
51. POLLARD, H., CLORENS, C., SCHWARTZ, J. C., GROS, C. AND DRAY, F.: Localization of opiate receptors and enkephalins in the rat striatum in relationship with the nigrostriatal dopaminergic system: Lesion studies. Brain Res. 151: 392-398, 1978.
52. QUAY, T., SLAUGHTER, C., DAVIS, T. P., MERRILL, B. J. AND HERSH, L. B.: Positional effects in the neprilysin (neutral endopeptidase) reaction. Arch Biochem. Biophys. 308: 133-136, 1994.
53. REID, M. S., HERRERA-MARSCHITZ, M., HÖKFELT, T., LINDEFORS, N., PERSSON, H. AND UNGERSTEDT, U.: Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: Evidence for direct regulatory mechanisms. Exp. Brain Res. 82: 293-303, 1990.
54. SCHOFFELMEER, A. N. M., HOGENBOOM, F. AND MULDER, A. H.: Inhibition of dopamine-sensitive adenylate cyclase by opioids: Possible involvement of physically associated μ- and δ-opioid receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 335: 278-284, 1987.
55. SEEMAN, P: Brain dopamine receptors. Pharmacol. Rev. 32: 229-313, 1980.
56. SKIDGEL, R. A., ENGELBRECHT, S., JOHNSON, A. R. AND ERDÖS, E. G.: Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptidea 5: 769-776, 1984.
57. TAN, D.-P. AND TSOU, K.: Differential effects of tachykinins injected intranigrally on striatal dopamine metabolism. J. Neurochem. 51: 1333-1337, 1988.
58. TURNER, A. J. AND BARNES, K.: Neuropeptidases: Candidate enzymes and techniques for study. Biochem. Soc. Trans. 22: 122-127, 1994.
59. TURNER, A. J., MATSAS, R. AND KENNY, A. J.: Are there neuropeptide-specific peptidases? Biochem. Pharmacol. 34: 1347-1356, 1985.
60. UHL, G. R. AND SNYDER, S. H.: Regional and subcellular distribution of brain neurotensin. Life Sci. 19: 1827-1832, 1977.
61. WATERS, S. M., KONKOY, C. S. AND DAVIS, T. P.: Neuropeptide metabolism on intact, regional brain slices: Effect of dopaminergic agents on substance P, cholecystokinin and met-enkephalin degradation. J. Pharmacol. Exp. Ther. 274: 783-789, 1995.
62. WEST, C. H. K. AND MICHAEL, R. P.: Substance P injections into the ventral tegmentum affect unit activity in mesolimbic terminal regions. Brain Res. Bull. 26: 229-233, 1991.
63. YANG, H. Y. T., ERDOS, E. G. AND LEVIN, Y.: Adipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochem. Biophys. Acta 214: 374-376, 1970.
64. YANG, H. Y. T. AND NEFF, N. H.: Distribution and properties of angiotensin converting enzyme of rat brain. J. Neurochem. 19: 2443-2450, 1972.